Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

romiplostim × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 7 Lymphoid 5 Plasma cell 3 Thoracic 2 Gynecologic 2 Sarcoma 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Gastrointestinal 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Interventions

pembrolizumab 288 Nivolumab 258 Ipilimumab 230 Cyclophosphamide 168 aldesleukin 129 Interleukin-2 92 fludarabine phosphate 87 trametinib 77 fludarabine 71 dabrafenib 67 Radiotherapy 67 Dacarbazine 66 Temozolomide 65 Biopsy 63 Vemurafenib 60 Imiquimod 48 Radiosurgery 46 Bevacizumab 46 Magnetic Resonance Spectroscopy 44 sargramostim 43 Specimen Handling 41 Blood Specimen Collection 41 Aminolevulinic Acid 41 Peripheral Blood Stem Cell Transplantation 40 3-ingenyl angelate 40 Cisplatin 39 cemiplimab 38 Paclitaxel 38 atezolizumab 36 Carboplatin 36

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04427306 2023-09-15

Neoadjuvant T-VEC in High Risk Early Melanoma

University of California, Davis

Phase 2 Suspended

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡